Advertisement
Canada markets open in 1 hour 41 minutes
  • S&P/TSX

    21,740.20
    -159.79 (-0.73%)
     
  • S&P 500

    5,061.82
    -61.59 (-1.20%)
     
  • DOW

    37,735.11
    -248.13 (-0.65%)
     
  • CAD/USD

    0.7256
    +0.0003 (+0.04%)
     
  • CRUDE OIL

    85.07
    -0.34 (-0.40%)
     
  • Bitcoin CAD

    86,242.48
    -4,880.77 (-5.36%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,389.20
    +6.20 (+0.26%)
     
  • RUSSELL 2000

    1,975.71
    -27.47 (-1.37%)
     
  • 10-Yr Bond

    4.6280
    0.0000 (0.00%)
     
  • NASDAQ futures

    17,900.75
    +24.50 (+0.14%)
     
  • VOLATILITY

    18.92
    -0.31 (-1.61%)
     
  • FTSE

    7,860.39
    -105.14 (-1.32%)
     
  • NIKKEI 225

    38,471.20
    -761.60 (-1.94%)
     
  • CAD/EUR

    0.6818
    -0.0006 (-0.09%)
     

How the Gov Helped Create a $3 to $300 Stock Windfall, and Could Do it Again

- The Human Genome Project changed the scientific landscape completely, spurring major public and private investment into understanding human DNA. We're still benefitting from this effort as the science bears fruit in the form of new healthcare technology and even public market winners: ILMN, for example, has gone from $3 to $300 in the last 15 years - A newer government-backed effort called the BRAIN Initiative seeks to map the human brain, similar in scope to the Human Genome project. This initiative will fund major progress in neurology in the same way, and it coincides with a recent surge in investor interest in new technology targeting the nervous system - A wave of companies devoted to ''neurostimulation'' recently came into the public markets to much investor interest: Nuvectra (NVTR), Nevro (NVRO), and ElectroCore (ECOR) are well-known examples. Nexeon Medsystems Inc. (NXNN) is one of the smallest, but as a BRAIN Initiative grant ... Click here to view full article